生物/靶向合成改善病情抗风湿药不能阻止类风湿关节炎患者的骨丢失:一项多中心前瞻性观察研究
这项多中心前瞻性观察研究纳入1164例首次使用生物/靶向合成改善病情抗风湿药(b/tsDMARDs)的类风湿关节炎(RA)患者,随访52周。基线未用抗骨质疏松药且无骨折史者,股骨颈和桡骨骨密度在第26周显著下降,第26-52周虽维持低疾病活动度但骨密度仍持续下降;基线用抗骨质疏松药者骨密度保持稳定。骨转换标志物的变化与骨密度变化无关。
要点
- 基线未用抗骨质疏松药的RA患者,b/tsDMARDs治疗26周股骨颈和桡骨骨密度显著下降。
- 第26-52周虽维持低CDAI水平,骨密度仍持续下降。
- 基线用抗骨质疏松药者骨密度在整个研究期间保持稳定。
核心结论
- 研究提示,RA患者在接受b/tsDMARDs治疗但未联用抗骨质疏松药期间,骨质疏松仍在进展。
- 骨转换标志物可能不反映骨密度变化。
- 作者认为,RA患者应考虑定期监测骨密度以早期管理骨质疏松。
研究设计与样本
- 多中心前瞻性观察研究,纳入首次使用b/tsDMARDs的RA患者,计划入组所有符合条件的RA患者。
- 共纳入1164例患者,观察52周,测量骨密度和骨转换标志物。
- 终点为不同b/tsDMARD类型间骨密度变化的差异,以及骨密度与骨转换标志物的相关性。
主要发现
- b/tsDMARDs将RA疾病活动度从基线平均CDAI 25.5改善至第26周4.5。
- 基线未用抗骨质疏松药且无骨折史者,第26周股骨颈骨密度从平均0.666 g/cm3降至0.655 g/cm3,桡骨从0.518降至0.514。
- 第26-52周CDAI维持在5.3-4.4的低水平,但骨密度继续下降,第52周股骨颈为0.653、桡骨为0.509。
- 基线用抗骨质疏松药者骨密度保持稳定,第0/26/52周股骨颈为0.551/0.551/0.555,桡骨为0.415/0.416/0.415。
- 骨转换标志物虽受b/tsDMARDs影响,但其变化与骨密度变化无关。
临床怎么用
- 作者认为,RA患者应考虑定期监测骨密度以早期管理骨质疏松。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To elucidate the differential effects of biological/target synthesized DMARDs (b/tsDMARDs) on bone metabolism in patients with rheumatoid arthritis (RA) in a real-world cohort. METHODS: This was a multicentre prospective observational study of RA patients enrolled at the time of first b/tsDMARDs administration. Bone mineral density (BMD) and bone turnover markers (BTMs) were measured during the 52-week observation. The study was designed to enrol all eligible RA patients. The end-points were differences in changes in BMD according to b/tsDMARD type, and the correlation between BMD and BTMs. RESULTS: A total of 1164 patients were enrolled in this study. b/tsDMARDs improved RA disease activity from mean CDAI 25.5 at baseline to 4.5 at week 26. Patients not receiving anti-osteoporotic agents (anti-OP) at baseline with no history of fracture experienced a significant decrease in both femoral neck (F: mean 0.666-0.655 g/cm3) and radial (R: 0.518-0.514) BMD at week 26. Despite maintaining low CDAI levels during weeks 26-52 (5.3-4.4), there was a continued decline in BMD (F: 0.653, R: 0.509. Weeks 52). None of the b/tsDMARDs type preserved BMD. Conversely, patients receiving anti-OP at baseline maintained stable BMD throughout the study (Weeks 0/26/52. F: 0.551/0.551/0.555, R: 0.415/0.416/0.415). Although BTMs were changed by b/tsDMARDs, the changes were unrelated to those in BMD. CONCLUSION: Our study suggested the progression of osteoporosis in RA patients during b/tsDMARDs treatment without anti-OP. BTMs may not reflect BMD change. Regular monitoring of BMD in RA should be considered for early management of osteoporosis.
引用
- Sonomoto K, Nakayamada S, Fujino Y, et al. Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study. Rheumatology (Oxford). 2024. PMID: 37934120. doi:10.1093/rheumatology/kead579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。